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Pathogenic bacteria have increasingly been resisting to antimicrobial therapy. Re-
cently, resistance problem has been relatively much worsened in Gram-negative 
bacilli. Acinetobacter spp. are typical nosocomial pathogens causing infections 
and high mortality, almost exclusively in compromised hospital patients. Acineto-
bacter spp. are intrinsically less susceptible to antibiotics than Enterobacteriaceae, 
and have propensity to acquire resistance. A surveillance study in Korea in 2009 
showed that resistance rates of Acinetobacter spp. were very high: to fluoroquino-
lone 67%, to amikacin 48%, to ceftazidime 66% and to imipenem 51%. Carbape-
nem resistance was mostly due to OXA type carbapenemase production in A. bau-
mannii isolates, whereas it was due to metallo-β-lactamase production in non-
baumannii Acinetobacter isolates. Colistin-resistant isolates were rare but started 
to be isolated in Korea. Currently, the infection caused by multidrug-resistant A. 
baumannii is among the most difficult ones to treat. Analysis at tertiary care hospi-
tal in 2010 showed that among the 1,085 isolates of Acinetobacter spp., 14.9% and 
41.8% were resistant to seven, and to all eight antimicrobial agents tested, respec-
tively. It is known to be difficult to prevent Acinetobacter spp. infection in hospi-
talized patients, because the organisms are ubiquitous in hospital environment. Ef-
forts to control resistant bacteria in Korea by hospitals, relevant scientific societies 
and government agencies have only partially been successful. We need concerted 
multidisciplinary efforts to preserve the efficacy of currently available antimicrobi-
al agents, by following the principles of antimicrobial stewardship.
Key Words:    Acinetobacter baumannii, multidrug resistance, OXA type carbapen-
emase, metallo-β-lactamase
INTRODUCTION
Antimicrobial agents (antibiotics) are extremely important drugs to fight against 
bacterial infections.1 When antibiotics were first introduced in the 1940s, they 
were considered as “miracle drugs”: highly fatal pneumococcal pneumonia and in-
fant meningitis patients could be saved and syphilis became easily controllable in-
fection with penicillin G, and tuberculosis could be cured with streptomycin. With 
the use of antibiotics, major surgery became a relatively safe procedure, and can-Kyungwon Lee, et al.
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cer patients were protected during the critical period of de-
creased leucocytes due to chemotherapy.
However, bacteria have increasingly been resisting to an-
timicrobial therapy. In general, new resistances have been 
detected soon after introduction of new antimicrobial agents 
(Table 1). To cope with resistant bacteria, new antimicrobi-
al agents had to be developed, but it became increasingly 
difficult to find new ones.2 Now, we know that emergence 
of antibiotic resistance is an inevitable consequence when 
we use antibiotics. Therefore, we must seek to decrease its 
impact and prolong the effectiveness of currently available 
antimicrobial agents.3 
In 1998, Yonsei Medical Journal published a special is-
sue on antibiotic resistance (Vol. 39, No. 6), because we 
considered that antibiotic resistance reached a very seri-
ous state in Korea. At that time, the most concerned resis-
tances were those of nosocomial pathogens: extended-
spectrum β-lactamase (ESBL)- and plasmid-mediated 
AmpC β-lactamase (PABL)-producing Enterobacteriace-
ae, methicillin-resistant Staphylococcus aureus (MRSA), 
and vancomycin-resistant Enterococcus faecium (VRE). 
Despite efforts to control resistant bacteria, however, Gram-
positive nosocomial pathogens, MRSA and vancomycin-
resistant E. faecium became more prevalent in many coun-
tries,4 and resistance problem has relatively worsened in 
Gram-negative bacilli.5,6 
Acinetobacter baumannii causes various nosocomial in-
fections with high mortality, and the infection caused by 
multidrug-resistant A. baumannii is currently among the 
most difficult ones to treat.7 A few extensive reviews have 
been published on Acinetobacter bacteriology and infec-
tion.8-10 In most Asian countries, including Korea, Acineto-
bacter infections are relatively more prevalent and the or-
ganisms are more often resistant.11 Therefore, it seems to be 
an appropriate time to review the current status of resis-
tance in general and that of the most feared Acinetobacter 
spp. in Korea in particular to help understand and alleviate 
this serious problem.
 
TAXONOMY AND PATHOGENICITY  
OF ACINETOBACTER SPP.
 
The genus Acinetobacter comprises Gram-negative, aero-
bic, glucose-nonfermenting, nonfastidious, nonmotile, cata-
lase-positive, and oxidase-negative bacteria. The taxonomy 
of Acinetobacter has been confused for a long time. Before 
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ruginosa, however, Acinetobacter spp. survived on both 
moist and dry surfaces.18 These characteristics are benefi-
cial for the organism to survive in hospital environments 
and cause infection. Acinetobacter spp. are typical nosoco-
mial pathogens causing infections almost exclusively in 
compromised patients. Even the Acinetobacter infections in 
soldiers were considered to be acquired during admission 
to medical facilities, rather than from the environment at 
the time of wounding.19 Acinetobacter spp. are more com-
monly isolated than S. aureus and Pseudomonas spp. from 
inanimate surfaces, and hands of staff in the ICU.18 It is dif-
ficult to determine significance of recovery of Acinetobacter 
spp. from clinical materials, because of their frequent colo-
nization rather than infection (Fig. 1).
Although it is somewhat difficult to make a direct com-
parison due to difference in the methods used, it is apparent 
that proportion of Acinetobacter spp. was much higher in 
Korea and Taiwan than in the U.S. For example in a U.S. 
study in 2006-2007, the proportion of A. baumannii was 
2.7% and the rank order was 9 among the isolates from 
healthcare-associated infections.20 In a Korean study in 
2009, the proportion was 6.6% and rank order was 7.21 An 
analysis at a Taiwanese hospital in 1996 to 2003 showed 
that the proportions of both A. baumannii and E. coli were 
8% among all nosocomial blood stream isolates.22 
In a Korean study involving 28 OXA carbapenemase-
producing A. baumannii bloodstream infections, the 30 day 
the designation of genus Acinetobacter in 1954, the organ-
isms had been known as at least 15 different genera.10 Be-
sides 23 validly published Acinetobacter species (http://
www.bacterio.cict.fr), there are at least nine unnamed spe-
cies: genomic species 3, 6, 13TU, 13BJ, 14BJ, 15BJ, 15TU, 
16 and 17. Names of new species, A. pittii and A. nosoco-
mialis, were recently proposed for genomic sp. 3 and 13TU, 
respectively.12 
Species identification of Acinetobacter spp., based on ab-
breviated phenotypic tests, is mostly difficult, resulting in 
overestimation of prevalence of A. baumannii. By original 
phenotypic tests, the proportion of A. baumannii was 78.1% 
among the Acinetobacter isolates mostly from France,13 
whereas that from Germany was 72.9%  (Table 2).8 Using 
phenotypic and molecular methods, 80.5% of French iso-
lates were identified as A. baumannii.14 Based on sequenc-
ing of 16-23S rRNA intergenic spacer region,15 70.9% of 
Acinetobacter spp. isolates in a Korean study were identi-
fied as A. baumannii. Of note was the fact that the propor-
tion of A. baumannii was 95.4% among the isolates from 
tracheal aspirates, whereas it was only 59.1% among those 
from blood and central venous line.13 
It was shown experimentally that the majority of A. bau-
mannii strains survive longer than Escherichia coli on dry 
surfaces, and some strains survive for more than 4 months.16 
In another study, A. baumannii survived for over 20 days 
on glass surfaces at room temperature.17 In contrast to P. ae-
Table 2. Prevalent Acinetobacter spp. in Clinical Specimens*
Species (genomic sp.)
No. (%) of isolates from
Bouvet and Grimont
13 
(n=334)
Bergogne-Bérézin and 
Towner
8 (n=584)  Dortet, et al.
14 (n=456) Lee, et al.
15 (n=547)
A. baumannii (2) 261 (78.1) 426 (72.9)  367 (80.5)
† 388 (70.9)
A. johnsonii (7) 14 (4.2) 29 (4.9)   4 (0.9)
A. lwoffii (8-9) 16 (4.8) 21 (3.5) 26 (5.7)
A. junii (5)   1 (0.3) 11 (1.8) 10 (2.2)
A. haemolyticus (4) 12 (3.6)   9 (1.5) 14 (3.1)
A. bereziniae (10)   9 (1.5) 13 (2.4)
A. guillouiae (11)   4 (0.6)
Genomic sp. 3 20 (6.0) 55 (9.4)   8 (1.8)   62 (11.3)
                      6   1 (0.1)
                      12   2 (0.6)   3 (0.5)
                      13TU   2 (0.4)   82 (15.0)
                      14TU   2 (0.4)
                      Others    8 (2.4)
‡   16 (2.7)
||   25 (5.5)
§
*Method of identification: references 13 and 8, phenotypic; 14, phenotypic and molecular; 15, molecular.
†353 isolates were identified as A. calcoaceticus-A. baumannii by phenotypic tests, all others were identified by molecular method. 
‡Genomic sp. (GS) 10 (n=1), GS 11 (n=1), unidentified (n=6).
§A. ursingii (n=10), A. schindleri (n=5), A. radioresistens (n=3), GS 15TU (n=4), GS 17 (n=1), GS 16BJ (n=1), and GS 10 (n=1).
||Unidentified.Kyungwon Lee, et al.
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ems remained active against most of these organisms, but 
increased use of this class of antimicrobials to treat infec-
tion of 3rd generation cephalosporin-resistant Gram-nega-
tive bacilli resulted in emergence of carbapenem-resistant 
P. aeruginosa and Acinetobacter spp.27 The Korean surveil-
lance study21 showed that, during 1997 to 2009, imipenem-
resistant P. aeruginosa and Acinetobacter spp. increased 
from 17% to 26%, and from 1% to 51%, respectively. K. 
pneumoniae isolates with a new class A carbapenemase, 
KPC-2,30 and a new class B metallo-β-lactamase (MBL), 
NDM-1,31 emerged in the U.S. and in India, respectively. 
Enterobacteriaceae with the last two enzymes started to 
spread to other countries, including Korea.
 
 
ANTIMICROBIAL RESISTANCE IN 
ACINETOBACTER SPP.
  
Seven mechanisms of antibiotic resistance are known in 
Gram-negative bacteria: loss of porins, production of β-lacta-
mases, increased expression of efflux pumps, presence of an-
tibiotic-modifying enzymes, target site mutations, ribosomal 
mutations or modifications, metabolic bypass mechanisms, 
and a mutation in the lipopolysaccharide.32
Acinetobacter spp. are intrinsically less susceptible to an-
timicrobial agents than the species of Enterobacteriaceae. 
Outer membrane permeability of A. baumannii is less than 
5% compared with other Gram-negative bacilli, because of 
small number and size of porins.33 Porins are pore forming 
proteins on the outer membrane (OMP) of bacteria. Three 
OMPs (33-36 kDa, 29 kDa, and 43 kDa) have been report-
ed to be missing in the imipenem-resistant strains of A. 
baumannii. Decreased expression of OmpW was reported 
in a colistin-resistant A. baumannii mutant. 
All bacteria have efflux systems. The multidrug efflux 
pumps actively export multiple, structurally-distinct classes 
of antimicrobials out of the bacterial cell. The most com-
mon antimicrobials expelled by the efflux pumps are mac-
rolides, tetracyclines and quinolones.33 Overexpression of 
efflux pump further increases resistance level. Among the 
six families of multidrug efflux systems, major facilitator 
superfamily (MFS) and resistance-nodulation-division 
(RND) family are often associated with antimicrobial resis-
tance in A. baumannii. Tet(A) and Tet(B) pumps belong to 
the MFS, and confers resistance to tetracycline, and both 
tetracycline and minocycline, respectively. AdeM pump is a 
member of the multidrug and toxic compound extrusion   
mortality was 53.6% which was independently associated 
only with a high Pitt bacteremia score by multivariate anal-
ysis.23 Outbreaks of multidrug resistance (MDR) A. bau-
mannii occurred in 2007 at a Korean hospital, and involved 
17 patients with 13 deaths either from septic shock or from 
a combination of underlying diseases.24 
 
 
TRENDS IN ANTIMICROBIAL 
RESISTANT BACTERIA IN GENERAL
  
Certain bacterial species, which cause community-acquired 
infections more often, have been increasingly resistant to 
certain antibiotics, i.e., pneumococci to penicillin G, and E. 
coli and Klebsiella pneumoniae to 3rd generation cephalo-
sporins. However, the most feared resistant bacteria are 
those typically causing nosocomial infections. The Korean 
nationwide surveillance on antimicrobial resistance (KON-
SAR) studies in 1997 to 2009 showed that approximately 
70% of all S. aureus were resistant to methicillin, and VRE 
had increased significantly from 4% to 29%.21 In the U.S., 
proportion of MRSA was initially much lower than that in 
Asian countries. But, despite intensive efforts to control the 
spread, the rates in 2005 were 59.2% among isolates from 
non-ICU inpatients, and 55% among those from ICU pa-
tients.25 Vancomycin-resistant Enterococcus was first de-
tected in Europe and became prevalent in the U.S. In 2006 
and 2007, the proportion of vancomycin-resistance was 
78.9% among blood stream isolates of E. faecium.20 
As for the resistance of Gram-negative bacilli, ESBL- or 
PABL-producing E. coli and K. pneumoniae have emerg-
ed.26-28 In Korea, these enzyme-producing organisms have 
increasingly been detected since the late 1990s.29 Carbapen-
Fig. 1. Major reservoirs, sources, and transmission patterns for Acineto-
bacter infections in hospitalized patients. 
Hospital environment  
and others 
Respiratory and other  
equipment; water; bedding  
and furniture 
Hospitalized patients - infection or colonization
Shed Acinetobacter from respiratory tract, skin, wounds 
Hospitalized patients - infection or colonization
Health care workers
HandsMultidrug-Resistant Acinetobacter spp.
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strain AYE. 
Different definitions of the terms MDR and pandrug-re-
sistant (PDR) A. baumannii have been used in the literature 
causing confusion to microbiologist as well as to clini-
cians.39 In considerable proportion of the studies, MDR was 
defined as the resistance to representative antimicrobial 
agents of at least three different classes. The most common-
ly included antimicrobials were aminoglycosides, antipseu-
domonal penicillins, carbapenems, cephalosporins, and qui-
nolones. Colistin, ampicillin-sulbactam or tetracyclines 
(doxycycline or minocycline) were occasionally included. 
The suggested definition of PDR in A. baumannii included 
resistance to sulbactam, minocycline or doxycycline, and 
tigecycline in addition to all the above mentioned antimi-
crobials. This definition is similar to that of extreme drug 
resistance (XDR) proposed by Paterson and Doi40 in that it 
included resistance to tigecycline and polymyxins. Sulbac-
tam is a β-lactamase inhibitor with no significant antimicro-
bial activity, but peculiarly it has bactericidal activity 
against A. baumannii. However, in 2009, 57% of Acineto-
bacter spp. isolates were found to be resistant to ampicillin-
sulbactam.21 
In a Surveillance Network (TSN) study in the U.S.41 a large 
number of A. baumannii isolates were tested. The resistance 
trend was largely similar to that in Korea,42 although rates of 
nonsusceptibility were reported in the U.S. study, while rates 
of resistance were reported in the Korean study (Table 3). Ta-
ble 4 shows MDR patterns of Acinetobacter isolates from a 
Korean tertiary care hospital in 2009. Among the 1,085 iso-
lates, 308 (28.4%) were resistant to none of the eight antimi-
crobials, whereas 14.9% and 41.8% were resistant to seven 
and to all eight antimicrobial agents, respectively. In the 
study, colistin susceptibility was not tested because resistant 
isolates to this antimicrobial agent was extremely rare. 
(MATE) family, and confers resistance to norfloxacin, 
ofloxacin, ciprofloxacin, and gentamicin.33 AdeABC is a 
three-component efflux pump, where AdeA is the mem-
brane fusion protein, AdeB is the multidrug transporter, and 
AdeC is the OMP. AdeABC pump belongs to the RND fam-
ily and confers resistance to aminoglycosides, β-lactams, 
chloramphenicol, erythromycin and tetracyclines, and re-
duced susceptibility to fluoroquinolones. 
A. baumannii carries intrinsic blaAmpC genes encoding Aci-
netobacter-derived cephalosporinases which confer natural 
resistance to cefoxitin. as are many other species of Gram-
negative bacilli.34 Inducible AmpC expression does not oc-
cur in A. baumannii, unlike that of AmpC enzymes found in 
other Gram-negative bacilli. Presence of upstream ISAba1 is 
involved in the overexpression of this gene, resulting in re-
sistance to 3rd generation cephalosporins.35,36 A. baumannii 
also naturally carries intrinsic blaOXA-51-like genes, and pres-
ence of upstream ISAba1 renders the organism resistant to 
carbapenems. ISAba1, ISAba2, ISAba3, and ISAba4 could 
increase expression of blaOXA-51-like genes. Increased ex-
pression of blaOXA-23 by the upstream ISAba10 was reported 
in a group of A. baumannii isolates.37 
 
Multi-drug resistance
The most serious current problem in the treatment of Aci-
netobacter infection is acquired MDR, thus leaving few an-
timicrobial agents to use. MDR could be due to bacterial 
possession of a resistant determinant which confers resis-
tance to more than one class of antimicrobial agents. MDR 
pump is one of the examples. MDR is also due to posses-
sion of multiple resistance determinants.32 Acinetobacter is 
an organism that appears to have a propensity to extremely 
rapidly develop antibiotic resistance.8 Fournier, et al.38 de-
tected 45 acquired resistance genes in a MDR A. baumannii 
Table 3. Resistance Rates of Acinetobacter Isolates from Korea and from the U.S.
Antimicrobial agents Isolates from
% of isolates resistant (Korea) or nonsusceptible (U.S.)
2003 2005 2007 2008/2009*
Fluoroquinolone Korea 58 51 45 67
U.S. 60 64 69 72
Amikacin Korea 55 43 37 48
U.S. 55 59 56  59
† 
Ceftazidime Korea 54 56 50 66
U.S. 64 67 73  75
‡
Imipenem Korea 13 16 22 51
U.S. 21 34 43 52
*Year of isolation: the U.S. in 2008 and Korea in 2009. 
†Amikacin or gentamicin.
‡Ceftazidime or cefepime.Kyungwon Lee, et al.
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one of each genomic species 3 and unidentifiable Acineto-
bacter sp. were A. baumannii. The isolates were mostly 
from sputum specimens from ICU patients, and all of them 
were resistant to ceftazidime, cefotaxime, cefepime, and az-
treonam. In another study, PER-1 was detected in 78.6% of 
42 outbreak-associated isolates from a Korean hospital in 
2007.24 
 
MBLs 
MBLs are molecular class B and functional group 3 β-lacta-
mases which have the capability of hydrolyzing all β-lactams 
except the monobactam, aztreonam.46 Carbapenem-hydro-
lyzing activity of MBL is very potent. After introduction of 
imipenem into clinical practice, IMP-type and VIM-type 
MBL-producing Gram-negative bacilli emerged in Japan 
and Italy, respectively.10 In Korea, the first MBL detected 
was VIM-2 in P. aeruginosa in 1995,47 and then VIM-2 and 
IMP-1 were detected in Acinetobacter spp. in 1998.48 Of 
ESBLs 
There are only few studies on ESBLs in A. baumannii. 
Spread of A. baumannii strains with TEM-92 in Italy, with 
SHV-12 in China, and with TEM-116 and SHV-12 in the 
Netherlands has been reported.10 CTX-M type ESBL are 
prevalent among Enterobacteriaceae, but a small number 
of Acinetobacter isolates with CTX-M-2, CTX-M-43, and 
CTX-M-15 have been described from Japan, Bolivia, and In-
dia, respectively.10 Vietnam extended-spectrum β-lactamase 
(VEB-1) was first detected in an E. coli isolate from a Viet-
namese child. Dissemination of VEB-1-producing A. bau-
mannii was reported from France,43 and then from Belgium 
and Argentina.10 
Pseudomonas extended resistant (PER) type ESBL, ini-
tially detected in P. aeruginosa from France in 1991,44 has 
been detected in Acinetobacter isolates from many coun-
tries.10 In Korea, PER-1 was detected in 54.6% of 97 con-
secutive Acinetobacter isolates.45 All of the isolates except 
Table 4. Multiresistance Patterns of 1,085 Acinetobacter Isolates from a Korean Tertiary Care Hospital in 2009
Resistance to No.  
  of antibiotics*
Resistance pattern 
No. of isolates SXT LVX PIP CAZ FEP SAM IPM AMK
2 (14; 1.3%) (4)
† 2 × ×
5 × ×
3 × ×
3 (17; 1.6%) (1)
† 3 × × ×
6 × × ×
2 × × ×
5 × × ×
4 (9; 0.8%) (5)
† 4 × × × ×
5 (12; 1.1%) (3)
† 3 × × × × ×
2 × × × × ×
2 × × × × ×
2 × × × × ×
6 (34; 3.1%) (5)
† 2 × × × × × ×
3 × × × × × ×
11 × × × × × ×
5 × × × × × ×
3 × × × × × ×
5 × × × × × ×
7 (162; 14.9%) 104 × × × × × × ×
8 × × × × × × ×
38 × × × × × × ×
7 × × × × × × ×
5 × × × × × × ×
8 (453; 41.8%) 453 × × × × × × × ×
SXT, trimethoprim-sulfamethoxazole; LVX, levofloxacin; PIP, piperacillin; CAZ, ceftazidime; FEP, cefepime; SAM, ampicillin-sulbactam; IPM, imipenem; 
AMK, amikacin.
*No. and % of isolates are shown in parenthesis. Among the isolates, 308 (28.4%) were resistant to none of the antibiotics, and 76 (7.0%) were resistant 
to one of the eight antibiotics (36 to PIP, 15 to SXT, 12 to CAZ, 7 to AMK, 3 to. LVX, 2 to FEP, 1 to SAM).
†Total number of isolates omitted for the patterns with only one isolate each.  Multidrug-Resistant Acinetobacter spp.
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mannii with OXA-23 were found to have identical or close-
ly related PFGE patterns, indicating that rapid increase of 
this determinant was due to clonal spread.56 In a Korean 
surveillance study in 2000-2001, only 27 of 267 (10.1%) 
imipenem-nonsusceptible Acinetobacter spp. isolates had 
MBLs.57 In another study in 2005,53 vast majority of imipe-
nem resistance in Acinetobacter spp. isolates were due to 
OXA carbapenemase production: among the 144 imipen-
em-resistant isolates only 19.4% had MBLs, whereas 74.3% 
had OXA carbapenemases.
Prevalent types of OXA carbapenemase varied signifi-
cantly depending on reports in Korea. In a surveillance 
study in 2005,53 among the 105 imipenem-resistant isolates 
of A. baumannii, 47 had blaOXA-23-like and 56 had upstream 
ISAba1-associated blaOXA-51-like genes. In another study in 
2007,58 among 178 isolates of A. baumannii, isolates with 
blaOXA-23-like genes were more prevalent (80%) than those 
with ISAba1-asssociated blaOXA-51-like genes (12%). It is of 
an interest to note in this study that 12 isolates had a novel 
blaOXA-182 which is related to blaOXA-143, first reported in Bra-
zil in 2004.59 At a Taiwanese regional hospital, among imi-
penem-resistant A. baumannii isolates, blaOXA-23-like gene 
was detected in only 2 of 97 isolates in 2005 and 2006, but 
the gene was detected in 24 of 38 isolates in 2007.60 Pres-
ence of an identical PFGE type in 18 of the 38 isolates indi-
cated that the rapid increase was due to outbreaks. In a 
study, among 544 Acinetobacter isolates collected from 10 
Asia Pacific countries in 2006-2007,61 230 (42.3%) were 
nonsusceptible to carbapenems and OXA-23 was detected 
in 134 of 156 A. baumannii isolates from China, Hong 
Kong, India, Korea, Singapore, and Thailand. A. baumannii 
isolates from China, Indonesia, Taiwan and Thailand car-
ried other OXA carbapenemase: OXA-24/40 (n=5), OXA-
58 (n=2), OXA-23 plus OXA-58 (n=11), OXA-24 plus 
OXA-58 (n=1), and OXA-23 plus OXA-24/40 plus OXA-
58 (n=3). PFGE showed clonal dissemination of OXA car-
bapenemase-producing A. baumannii isolates within medi-
cal centers among different countries.
 
Aminoglycoside resistance 
Aminoglycosides have been important antibiotics for treat-
ment of serious bacterial infections, especially those with 
aerobic Gram-negative bacteria. However, bacteria became 
increasingly resistant to aminoglycosides by acquiring plas-
mid-borne genes encoding aminoglycoside-modifying en-
zymes, N-acetyltransferases (AAC), O-nucleotidyltransfer-
ases (ANT), or O-phosphotransferases (APH). Many of the 
several MBLs, only IMP, VIM, and SIM types have been de-
tected in Acinetobacter spp.10 In a surveillance study in 2003-
2004, MBLs were detected in 135 of 545 (24.8%) imipen-
em-resistant Acinetobacter spp. isolates. The proportions of 
IMP-1, VIM-2, and SIM-1 were 61%, 33%, and 6%, respec-
tively.49 A study in 2006 showed that, among 31 carbapen-
em-resistant Acinetobacter spp., IMP-1 was detected in 15 
(48.4%) isolates, whereas VIM-2 was detected in only one 
isolate,50 possibly because the isolates tested were small in 
number and were from only three hospitals.  
In the majority of earlier Korean studies, MBL-produc-
ing Acinetobacter spp. had been reported as A. baumannii, 
based on abbreviated phenotypic tests, which are now 
known to be mostly unreliable. Genetic identification of 58 
Acinetobacter spp. isolates showed that 40 were A. bau-
mannii, 9 were genomic sp. 13TU, 5 were phenon 6/ct 
13TU, and 4 were genomic sp. 3.51 However, among the 13 
MBL-producing isolates, 5 each were genomic sp. 13TU 
and phenon 6/ct 13TU, and 2 were genomic sp. 3, and only 
one was A. baumannii. In another study, it was shown that, 
among the imipenem-resistant isolates, all 14 isolates of 
Acinetobacter genomic sp. 13TU carried blaVIM-2, whereas 
13 A. baumannii carried blaOXA-23 or blaOXA-51.52 In a Korean 
surveillance study, all 28 MBL-producing isolates were 
non-baumannii Acinetobacter.53 Likewise, in a Taiwanese 
study, among 75 MDR Acinetobacter isolates, all three 
VIM-11- or IMP-1-producing isolates were genomic sp. 
13TU.36 These results indicate necessity of caution in re-
porting phenotypically-identified species of MBL-produc-
ing Acinetobacter spp. 
 
OXA carbapenemases
OXA-type β-lactamases are molecular class D enzymes.46 
OXA type enzymes continued to increase and became out-
numbered TEM types, i.e., 204 vs. 182 as of April 2011 
(www.lahey.org). OXA-type β-lactamases include narrow 
spectrum, extended-spectrum, and carbapenem-hydrolyz-
ing ones. Of the OXA type β-lactamases, those with car-
bapenemase activity are the most concerned. The first OXA-
type carbapenemase, OXA-23, was detected in 1985 from 
an A. baumannii strain from Scotland. The blaOXA-23 gene 
was located on transferable plasmid. Four main groups of 
OXA carbapenemases include OXA-23-like, OXA-40-like, 
OXA-51-like, and OXA-58 enzymes.54 
An outbreak of A. baumannii with OXA-23 was first re-
ported at a Korean hospital in 2003 involving 36 patients.55 
At another hospital in 2006-2007, all 49 isolates of A. bau-Kyungwon Lee, et al.
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mannii were nonsusceptible to ciprofloxacin in a U.S sur-
veillance study in 2000.66 In a Korean study, the MIC of 
ciprofloxacin was ≥64 μg/mL for 31 of 35 imipenem-resis-
tant and MDR A. baumannii isolates, and the isolates had 
mutations in both gyrA and parC.67 
Plasmid-mediated quinolone resistance genes have been 
detected in many Enterobacteriaceae spp.,68 but qnrA was 
first reported in an environmental isolate of A. baumannii 
from Algeria in 2008.69 qnr genes do not render a wild-type 
organism fluoroquinolone nonsusceptible, but the low-level 
resistance conferred by this mechanism enhances selection 
of fluoroquinolone-resistant Enterobacteriaceae mutants.70 
 
Tetracycline and tigecycline resistance
Resistance to tetracyclines and their derivatives can be me-
diated by efflux or ribosomal protection. tet(A) to tet(E) 
genes encoding tetracycline specific efflux pumps are often 
detected in Gram-negative bacilli, however, the tet(A) and 
tet(B) determinants have thus far been detected in A. bau-
mannii.10 Tet(A) confers resistance to tetracycline but not 
minocycline, an agent with greater activity against A. bau-
mannii. Tigecycline is a new glycylcycline and is a deriva-
tive of minocycline. Tigecycline appears as a promising 
therapeutic option for MDR A. baumannii. In a study using 
global collection of Acinetobacter spp. isolates, the MIC 
range of tigecycline was ≤0.008-8 μg/mL and MIC creep 
was reported between 2004 and 2007.71 Apart from tetracy-
cline-specific efflux pumps, this class of antimicrobial is 
also susceptible to efflux by the multidrug efflux systems, 
such as AdeABC, and AdeIJK pumps. Tigecycline is also 
extruded by these three-component RND efflux systems.72 
In a Korean study, all 43 imipenem-resistant A. baumannii 
isolates were susceptible to colistin, while 44% of them were 
not susceptible to tigecycline.73 In another study, 14 of 145 
(9.7%) colistin-resistant Acinetobacter spp. isolates were not 
susceptible to tigecycline.74 In a Spanish study, the MIC 
ranges of tigecycline and minocycline were 0.03-8 μg/mL 
and ≤0.06-32 μg/mL, respectively, for 150 isolates of A. bau-
mannii which included 61 colistin-resistant ones.75 It was 
reported that two patients developed A. baumannii blood-
stream infection while receiving tigecycline. The MICs of ti-
gecycline for the two isolates were 4 and 16 μg/mL, respec-
tively.76 
 
Polymyxin resistance
Polymyxins (colistin and polymyxin B) are polypeptide an-
timicrobial agents active against almost all Gram-negative 
genes encoding aminoglycoside-modifying enzymes are 
associated with transposons, which aid in the rapid dissemi-
nation of the resistance gene even between different spe-
cies.62 Moreover, transposons may concomitantly carry other 
resistance determinants which contribute to multiresistance. 
In a study using 75 isolates of Acinetobacter spp., majority 
of which were recovered from injured military patients who 
returned from Iraq/Kuwait, 89% were resistant to at least 
three classes of antibiotics, and 15% were resistant to all 
nine antibiotics tested.63 Resistance rates to amikacin and 
tobramycin were 53% and 67%, respectively. The majority 
of aminoglycoside-modifying enzyme genes detected by 
PCR were aacC1 (56%), aadB (48%), and aphA6 (71%). 
aphA6 confers resistance to amikacin, gentamicin, kanamy-
cin, and neomycin.
Amikacin is insensitive to modification by the majority 
of the plasmid-encoded enzymes that confer resistance to 
kanamycin, gentamicin and tobramycin. Resistance rates of 
E. coli to gentamicin and tobramycin at a Korean hospital 
in 2010 were 27% and 10%, respectively, whereas that to 
amikacin was only 1%.  In contrast, resistance rates of Aci-
netobacter spp. to these three aminoglycosides were over 
53% (Antimicrobial Resistance Newsletter, Ser. No. 72; 
www.whonetkorea.org). armA is a plasmid-borne gene en-
coding 16S rRNA methylase, and this enzyme modifies the 
target of aminoglycosides and renders the bacteria highly 
resistant to all aminoglycosides. armA gene was detected in 
14 of 33 consecutive Acinetobacter spp. isolates from a 
Korean tertiary care hospital in 2005.64 All of the armA-
positive isolates were highly resistant (MIC >1,024 μg/mL) 
to amikacin, gentamicin, netilmicin, and tobramycin. In an 
investigation of highly aminoglycoside-resistant A. bau-
mannii isolates associated with outbreak in 2007, armA to-
gether with blaOXA-23 and blaPER-1 genes were detected in 23 
of 42 MDR A. baumannii isolates.24 Again, this is an exam-
ple of A. baumannii isolates carrying multiple resistance 
determinants. 
 
Fluoroquinolone resistance
The fluoroquinolones are widely used broad-spectrum anti-
microbial agents. This class antimicrobials inhibit bacterial 
DNA gyrase and DNA topoisomerase IV, which are the en-
zymes required for bacterial DNA replication. The primary 
mechanism for quinolone resistance is alterations in the tar-
get enzymes, GyrA and ParC.65 In a Korean surveillance 
study in 2009, 67% of the Acinetobacter spp. isolates were 
resistant to fluoroquinolone,21 whereas, 52.4% of A. bau-Multidrug-Resistant Acinetobacter spp.
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velop new antimicrobials active against multi-resistant 
Gram-negative bacilli, preserving the efficacy of currently 
available ones has become very important.82 
Antimicrobial stewardship is a method recommended to 
achieve the control of resistance.83 In 2001, WHO pub-
lished the global strategy for containment of antimicrobial 
resistance (WHO/CDS/CSR/DRS/2001.2). As antimicrobi-
al resistance is a multifaceted problem,84 various interven-
tions are required in bundle to prevent its emergence and 
spread. The strategies include (1) reduce reservoirs of resis-
tant bacteria, and execute infection-control measures to pre-
vent transmission of resistant bacteria, (2) improve diag-
nostics to identify the etiology of infections and help direct 
therapy, (3) develop new antibiotics and vaccines, and im-
prove the use of currently available vaccines, and (4) edu-
cate physicians and patients for the importance of reducing 
resistance. Most of these goals are considered to be difficult 
to achieve, since whole problem of resistance is intertwined 
with moral, social, political, and commercial issues.85 
The KONSAR program has been in operation since 
1988, and the Antimicrobial Resistance Newsletter (www.
whonetkorea.org) has been published. The program was 
initially initiated with supports from WHO. Later, the Kore-
an Nosocomial Infection Surveillance (KONIS) System 
was established by the Korean Society for Nosocomial In-
fection Control (KOSNIC) together with the government 
agencies. The main target of this surveillance is nosocomial 
urinary tract infection, blood stream infection, and pneumo-
nia in ICU patients.86 KOSNIC also has been performing 
government supported researches, and workshops, related 
to nosocomial infection control. High prevalence of resis-
tant Acinetobacter spp. is often due to clonal spread.24,55,56,87 
The primary goals for the control of MDR Acinetobacter 
spp. infection are to recognize its presence in a hospital, 
and control the spread.9 To reduce reservoirs, the U.S. gov-
ernmental agencies have mandated the MRSA screening 
programs, however, several specialists in infection control   
have questioned its appropriateness.88 It is a question con-
cerning the need for active surveillance for much less viru-
lent Acinetobacter spp. 
The prevalence of hospital-acquired infections could be 
as high as 25% in an ICU.89 In 2008-2009, nosocomial in-
fection rates in ICU patients per 1,000 patient days were 
4.80 for urinary tract infection, 3.27 for central line-associ-
ated blood stream infection, and 1.86 for ventilator-associ-
ated pneumonia.86 Some U.S. studies showed that control 
efforts achieved significant decrease in nosocomial infec-
bacilli. These antimicrobial agents bind to the cell mem-
brane of Gram-negative bacilli, and make it more perme-
able, leading to bacterial death. Colistin was discovered in 
the 1940s, but it has not been used systemically because of 
nephrotoxicity and neurotoxicity. However, it has recently 
been increasingly used to treat MDR Acinetobacter infec-
tions. 
Colistin-resistant Acinetobacter spp. isolates have been 
rare in Korea. In a study, none of the 139 imipenem-non-
susceptible A. baumannii isolates recovered from four hos-
pitals in 2006 showed resistance to colistin.77 However, 
30.6% of 214 A. baumannii isolates recovered between 
2002 and 2006 at two hospitals showed resistance to colis-
tin, although only 11.7% were resistant to meropenem,78 
suggesting possible further spreading of colistin resistant 
isolates in Korea in the near future. 
The mechanism of polymyxin resistance in Enterobacte-
riaceae involves modifications of lipid A, which reduce 
binding to polymyxins. A study suggested that the mecha-
nism of polymyxin resistance in A. baumannii is associated 
with mutations in pmrA and pmrB. PmrAB and PhoPQ are 
involved in sensing environmental pH, and Fe3+ and Mg2+ 
levels, leading to altered expression of a set of genes in-
volved in lipid A modification.79 However, another study 
showed that in vitro selected colistin-resistant variant from 
A. baumannii type strain ATCC 19606 did not have muta-
tions in either pmrA or pmrB.80 Instead, the variant had a 
deletion of nucleotide 90 within lpxA, which would result 
in premature termination of LpxA translation. lpxA is pre-
dicted to encode the UDP-N-acetylglucosamine acyltrans-
ferase that catalyzes the first step in the biosynthesis of lipid 
A, and therefore, lipopolysaccharide. Loss of lipid A lead-
ing to colistin resistance was also observed in a colistin-re-
sistant clinical A. baumannii isolate.
 
 
CONTROL OF ANTIMICROBIAL 
RESISTANT BACTERIA
  
Antimicrobial resistant bacteria emerge as a consequence 
of antimicrobial use whether it is appropriate or not (Table 
1). Resistance to broad spectrum antimicrobial agents is 
more common among nosocomial pathogens, and lax in 
control measures enhances spread of resistant bacteria and 
increase infection. We now know that, however hard we 
try, bacteria will always overcome whatever we do to 
them.81 Moreover, as it has been increasingly difficult to de-Kyungwon Lee, et al.
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lence of nosocomial pathogens possessing multiple resis-
tance determinants. In general, cost vs. benefit is a great 
obstacle to execute the antimicrobial stewardship program.
In summary, Acinetobacter spp. have become particular-
ly problematic nosocomial pathogens in Korea, partly due 
to clonal spread. It is difficult to prevent Acinetobacter spp. 
infection in hospitalized patient, because the organisms are 
ubiquitous in hospital environment. Recent clinical isolates 
of Acinetobacter spp. in Korea were often found to be mul-
tiresistant to carbapenems, fluoroquinolones, and amino-
glycosides. Carbapenem resistance was mostly due to OXA 
type carbapenemase production in A. baumannii isolates, 
whereas it was due to MBL production in non-baumannii 
Acinetobacter isolates. Colistin-resistant isolates were rare, 
but started to be isolated. Since our past experience shows 
that emergence and spread of resistant bacteria are inevita-
ble, we need concerted multidisciplinary efforts to preserve 
the activity of currently available antimicrobial agents by 
following the principles of antimicrobial stewardship. 
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